BiotechTube

YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia, Hypertension

Trial Timeline

Nov 1, 2013 → Jun 1, 2014

NCT ID
NCT01914432

About YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo

YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo is a phase 3 stage product being developed by Yuhan for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01914432. Target conditions include Hyperlipidemia, Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01914432Phase 3Completed

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
VK2809 + PlaceboViking TherapeuticsPhase 2
47
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
Diet+pravastatinDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
85
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
77
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
77
exenatideEli LillyPre-clinical
23
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
33
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
33
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
41
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
52
Rosuvastatin (Crestor)AstraZenecaApproved
85
simvastatin + EzetimibeMerckApproved
85
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
77
simvastatin 20 mg/ezetimibeMerckPhase 2/3
65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
77
Sitagliptin + PlaceboMerckPhase 2/3
65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)NovartisPhase 1
33

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85